Journal article
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
The European respiratory journal, Vol.60(1), p.2102532
07/14/2022
DOI: 10.1183/13993003.02532-2021
PMCID: PMC8841623
PMID: 34824060
Abstract
Although commonly used, dexamethasone within 48 h of admission was associated with increased 90-day mortality in patients hospitalised with COVID-19 not on oxygen and with no mortality benefit in patients on low-flow nasal cannula
https://bit.ly/3l2aqjb
Details
- Title: Subtitle
- Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
- Creators
- Kristina Crothers - University of WashingtonRian DeFaccio - VA Puget Sound Health Care SystemJanet Tate - Yale New Haven Health SystemPatrick R. Alba - University of UtahMatthew Bidwell Goetz - VA Greater Los Angeles Healthcare SystemBarbara Jones - University of UtahJoseph T. King - Yale New Haven Health SystemVincent Marconi - Atlanta VA Medical CenterMichael E. Ohl - University of IowaChristopher T. Rentsch - University of LondonMaria C. Rodriguez-Barradas - Michael E. DeBakey VA Medical CenterShahida Shahrir - University of WashingtonAmy C. Justice - Yale UniversityKathleen M. Akgün - Yale New Haven Health SystemVeterans Aging Cohort Study Clinical COVID-19 Working Group
- Resource Type
- Journal article
- Publication Details
- The European respiratory journal, Vol.60(1), p.2102532
- DOI
- 10.1183/13993003.02532-2021
- PMID
- 34824060
- PMCID
- PMC8841623
- NLM abbreviation
- Eur Respir J
- ISSN
- 0903-1936
- eISSN
- 1399-3003
- Publisher
- European Respiratory Society
- Grant note
- 1I0IRX003666-01 / Veterans Affairs Rehabilitation Research and Development 13-457; C19-20-406; MVP000 / ;
- Alternative title
- Dexamethasone in hospitalised COVID-19 patients not on respiratory support
- Language
- English
- Date published
- 07/14/2022
- Academic Unit
- Psychiatry; Internal Medicine
- Record Identifier
- 9984359947902771
Metrics
31 Record Views